The Consortium of Eosinophilic Gastrointestinal Disease Researchers has been funded by NIH grants for more than a decade
This week, ACG sent a letter to National Institutes of Health (NIH) Director Dr. Jay Bhattacharya, imploring the agency to recommit critical funding for CEGIR, a leading authority for research and treatment of eosinophilic gastrointestinal disorders (EGIDs).
Earlier this month, the NIH withdrew CEGIR’s grant application, citing a policy change.
The CEGIR team consists of 18 clinical sites across the United States, integrating expertise in various specialties such as pediatric and adult gastroenterology, allergy, immunology, and pathology.
ACG knows the impact on our local communities and patients will be profound, and we conveyed these concerns directly to the NIH. There are currently nearly 1,000 patients participating in clinical research through CEGIR who will abruptly lose their ability to participate and receive ground-breaking care if funding is not reinstated.